Early Development Scale-Up of a Structurally-Challenging 5-Lipoxygenase Activating Protein (FLAP) Inhibitor

被引：7

作者：

Mulder, Jason A. ^{[1
]}

Gao, Joe ^{[1
]}

Fandrick, Keith R. ^{[1
,3
]}

Zeng, Xingzhong ^{[1
]}

Desrosiers, Jean-Nicolas ^{[1
,4
]}

Patel, Nitinchandra D. ^{[1
]}

Li, Zhibin ^{[1
,5
]}

Rodriguez, Sonia ^{[1
]}

Lorenz, Jon C. ^{[1
]}

Wang, Jun ^{[1
]}

Ma, Shengli ^{[1
,6
]}

Fandrick, Daniel R. ^{[1
]}

Grinberg, Nelu ^{[1
,7
]}

Lee, Heewon ^{[1
]}

Bosanac, Todd ^{[2
]}

Takahashi, Hidenori ^{[2
,8
]}

Chen, Zhidong ^{[2
,9
]}

Bartolozzi, Alessandra ^{[2
]}

Nemoto, Peter ^{[2
,10
]}

Busacca, Carl A. ^{[1
]}

Song, Jinhua J. ^{[1
]}

Yee, Nathan K. ^{[1
]}

Mahoney, Paige E. ^{[2
]}

Senanayake, Chris H. ^{[1
]}

机构：

[1] Boehringer Ingelheim Pharmaceut Inc, Chem Dev US, 900 Ridgebury Rd, Ridgefield, CT 06877 USA

[2] Boehringer Ingelheim Pharmaceut Inc, Med Chem US, 900 Ridgebury Rd, Ridgefield, CT 06877 USA

[3] LAM Therapeut, 530 Old Whitfield St, Guilford, CT 06437 USA

[4] Pfizer Inc, 558 Eastern Point Rd, Groton, CT 06340 USA

[5] Locke Lord LLP, Brookfield Pl,200 Vesey St,20th Floor, New York, NY 10281 USA

[6] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA

[7] 274 Aspetuck Ridge Rd, New Milford, CT 06776 USA

[8] Schrodinger, 120 West 45th St,17th Floor,Tower 45, New York, NY 10036 USA

[9] 160 Willow Springs, New Milford, CT 06776 USA

[10] Synovel, 42 Lake Ave Ext 222, Danbury, CT 06811 USA

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2017年 / 21卷 / 09期

关键词：

PALLADIUM; DISCOVERY; POTENT; LICL; ACID;

D O I：

10.1021/acs.oprd.7b00202

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

A practical and efficient synthesis of the FLAP inhibitor 1 was developed addressing multiple scale-up and safety concerns posed by the established synthesis and utilized a resolution strategy (replacing supercritical fluid chromatography (SFC) separation) for expedient access to the key structural component of 1: the challenging chiral quaternary center. Also highlighted are in situ IR monitoring, condensation to form the 1,2,4-oxadiazole ring, and an efficient Suzuki-Miyaura coupling.

引用

页码：1427 / 1434

页数：8

共 50 条

[41] Initial Clinical Experience and PK/PD Relationships With AZD5718, a Novel Once Daily Oral 5-lipoxygenase Activating Protein (FLAP) Inhibitor, Intended for Patients With Coronary Arterial Disease
Ericsson, Hans
Nelander, Karin
Lagerstrom-Fermer, Maria
Balendran, Clare
Forsberg, Gun-Britt
Bhat, Maria
Chialda, Ligia
Gan, Li-Ming
Heijer, Maria
Kjaer, Magnus
Lambert, John
Lindstedt, Eva-Lotte
Whatling, Carl
Skrtic, Stanko
CIRCULATION, 2017, 136
[42] Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005
Hamilton, AL
Watson, RM
Wyile, G
OByrne, M
THORAX, 1997, 52 (04) : 348 - 354
[43] Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
Heerspink, Hiddo J. L.
Law, Gordon
Psachoulia, Konstantina
Connolly, Kathleen
Whatling, Carl
Ericsson, Hans
Knochel, Jane
Lindstedt, Eva-Lotte
MacPhee, Iain
KIDNEY INTERNATIONAL REPORTS, 2021, 6 (11): : 2803 - 2810
[44] Differential effects of cell density on 5-lipoxygenase (5-LO), five-lipoxygenase-activating protein (flap) and interleukin-1 beta (IL-1 beta) expression in human neutrophils
Jobin, C
Gauthier, J
INFLAMMATION, 1997, 21 (02) : 235 - 250
[45] Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
Knochel, Jane
Nelander, Karin
Heijer, Maria
Lindstedt, Eva-Lotte
Forsberg, Gun-Britt
Whatling, Carl
Shimada, Hitoshi
Han, David S.
Gabrielsen, Anders
Garkaviy, Pavlo
Ericsson, Hans
CLINICAL DRUG INVESTIGATION, 2021, 41 (10) : 895 - 905
[46] Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
Jane Knöchel
Karin Nelander
Maria Heijer
Eva-Lotte Lindstedt
Gun-Britt Forsberg
Carl Whatling
Hitoshi Shimada
David S. Han
Anders Gabrielsen
Pavlo Garkaviy
Hans Ericsson
Clinical Drug Investigation, 2021, 41 : 895 - 905
[47] The 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor GSK2190915, Reduces Cigarette Smoke-Induced Pulmonary Inflammation In The Mouse
Stebbins, K. J.
Broadhead, A. R.
Chapman, C.
Correa, L.
Santini, A. M.
Prodanovich, P.
Darlington, J.
Lee, C.
Baccei, C.
Zunic, J.
Stock, N.
Bain, G.
Evans, J. F.
Lorrain, D. S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[48] Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP)
Ho, Joseph D.
Lee, Matthew R.
Rauch, Charles T.
Aznavour, Kristen
Park, Jonathan S.
Luz, John G.
Antonysamy, Stephen
Condon, Bradley
Maletic, Milan
Zhang, Aiping
Hickey, Michael J.
Hughes, Norman E.
Chandrasekhar, Srinivasan
Sloan, Ashley, V
Gooding, Karen
Harvey, Anita
Yu, Xiao-Peng
Kahl, Steven D.
Norman, Bryan H.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2021, 1865 (02):
[49] Blockage of soluble epoxide hydrolase (sEH) enhances the anti-inflammatory effects of aspirin and the 5-lipoxygenase activation protein (FLAP) inhibitor MK886
Liu, Junyan
Yang, Jun
Inceoglu, Bora
Ulu, Arzu
Hwang, Sung-Hee
Hammock, Bruce D.
FASEB JOURNAL, 2008, 22
[50] Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
Follows, Richard M. A.
Snowise, Neil G.
Ho, Shu-Yen
Ambery, Claire L.
Smart, Kevin
McQuade, Barbara A.
RESPIRATORY RESEARCH, 2013, 14

← 1 2 3 4 5 →